<unk> , sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan.<unk>  is formulated as a solution that is nebulized and inhaled.<unk>  is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.
Revefenacin
Flurbiprofen
Celecoxib
Diprobase
Indoprofen
Fenoprofen
Loxoprofen
Aceclofenac